[CAS NO. 320-67-2] 5-Azacytidine

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [320-67-2]

Catalog

HY-10586

Brand

MCE

CAS

320-67-2

DESCRIPTION [320-67-2]

Overview

MDL	MFCD00006539
Molecular Weight	244.20
Molecular Formula	C8H12N4O5
SMILES	O[C@H]1[C@@H](O)[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO

For research use only. We do not sell to patients.

39 Publications Citing Use of MCE

Summary

5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes ^[1] ^[2] . 5-Azacytidine induces cell autophagy ^[4] .

IC50 & Target

DNMT1

Nucleoside Antimetabolite/Analog

Autophagy

In Vitro

Unmethylated CpG islands associated with a variety of genes become partially or fully methylated in tumors and can be reactivated by 5-Azacytidine ^[1] . 5-Azacytidine acts as weak inducers of erythroid differentiation of Friend erythroleukemia cells in the same concentration range where they affect DNA methyltransferase activity ^[2] . 5-Azacytidine inhibits L1210 cells with ID ₅₀ and ID ₉₀ values of 0.019 and circa 0.15 μg/mL, respectively ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TdR- ³ H incorporation is significantly inhibited when the animals are exposed to 5-Azacitidine (100 mg/kg, i.p.) for 2 hr or longer ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04603001	Eli Lilly and Company\|Loxo Oncology, Inc.	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)\|Chronic Myelomonocytic Leukemia (CMML)\|Myeloproliferative Neoplasms (MPNs)	December 1, 2020	Phase 1
NCT02129101	Mayo Clinic\|National Cancer Institute (NCI)	Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Essential Thrombocythemia\|Myelodysplastic Syndrome\|Myelodysplastic+Myeloproliferative Neoplasm\|Polycythemia Vera\|Previously Treated Myelodysplastic Syndrome\|Primary Myelofibrosis\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	May 2014	Phase 1
NCT05149378	The First Affiliated Hospital of Soochow University\|Jining Medical University\|The Second People´s Hospital of Huai´an\|First Affiliated Hospital Bengbu Medical College\|Northern Jiangsu Province People´s Hospital\|Affiliated Hospital of Nantong University\|Suzhou Hospital of Traditional Chinese Medicine	Acute T-Lymphocytic Leukemia	November 1, 2021	Phase 2
NCT00503984	University of Miami	Prostate Cancer\|Pain	May 2007	Phase 1\|Phase 2
NCT05603884	The First Affiliated Hospital of Xiamen University\|Chipscreen Biosciences, Ltd.\|CSPC Pharmaceutical Group Limited\|Fujian Provincial Hospital\|Fujian Cancer Hospital\|Zhangzhou manicipal hospital of Fujian Province\|Jieyang People´s Hospital\|Huizhou Municipal Central Hospital	Leukemia, Myeloid, Acute\|AML Stage, Adult	December 1, 2022	Phase 2
NCT02450877	Celgene	Leukemia, Myeloid, Acute	August 12, 2015	Phase 2
NCT04128501	M.D. Anderson Cancer Center	Acute Bilineal Leukemia\|Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia\|Mixed Phenotype Acute Leukemia\|T Acute Lymphoblastic Leukemia\|Therapy-Related Acute Myeloid Leukemia	May 5, 2020	Phase 2
NCT04266795	Takeda	Acute Myeloid Leukemia (AML)	October 13, 2020	Phase 2
NCT00446303	Groupe Francophone des Myelodysplasies\|Celgene Corporation	Leukemia, Myelocytic, Acute\|Myelodysplastic Syndromes	July 2006	Phase 2
NCT00496444	M.D. Anderson Cancer Center\|Celgene Corporation	Advanced Cancers	May 2005	Phase 1
NCT01748240	Groupe Francophone des Myelodysplasies\|Merck Sharp & Dohme LLC	Myelodysplastic Syndrome	March 2013	Phase 2
NCT01016600	Washington University School of Medicine\|Celgene Corporation	Leukemia, Myeloid, Acute	April 2010	Phase 1\|Phase 2
NCT01935947	National Cancer Institute (NCI)	Recurrent Non-Small Cell Lung Carcinoma\|Stage IIIA Non-Small Cell Lung Cancer\|Stage IIIB Non-Small Cell Lung Cancer\|Stage IV Non-Small Cell Lung Cancer	May 2013	Phase 2
NCT02265510	Incyte Corporation	Solid Tumors\|Advanced Malignancies\|Metastatic Cancer	September 10, 2014	Phase 1\|Phase 2
NCT00321711	Amgen	MDS\|Myelodysplastic Syndromes\|Thrombocytopenia	October 1, 2006	Phase 2
NCT01787487	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Myelofibrosis Transformation in Essential Thrombocythemia\|Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase\|Primary Myelofibrosis	March 13, 2013	Phase 2
NCT05126004	The First Affiliated Hospital of Soochow University	Thrombocytopenia, Isolated\|Stem Cell Transplant Complications	December 1, 2021	Phase 2
NCT03862157	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Chronic Eosinophilic Leukemia, Not Otherwise Specified\|Chronic Myelomonocytic Leukemia\|Chronic Neutrophilic Leukemia\|Essential Thrombocythemia\|Myelodysplastic Syndrome\|Myelodysplastic+Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Myeloid Neoplasm\|Myeloproliferative Neoplasm\|Myeloproliferative Neoplasm, Unclassifiable\|Overt Primary Myelofibrosis\|Polycythemia Vera\|Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase\|Prefibrotic+Early Primary Myelofibrosis	February 27, 2019	Phase 1\|Phase 2
NCT00901069	Shams Shakil\|Celgene\|University of Kentucky	Lymphoma\|Hodgkin Disease\|Lymphoma, Non-Hodgkin	May 2009	Phase 1
NCT03765541	University Hospital, Toulouse	Relapsed or Refractory Acute Myeloid Leukemia	January 13, 2020	Phase 3
NCT05282719	The First Affiliated Hospital of Soochow University	Myelodysplastic+Myeloproliferative Neoplasms\|Adult	April 2022	Phase 2
NCT02458235	University of California, San Francisco\|Hellman Foundation	Acute Myelogenous Leukemia\|Acute Lymphoid Leukemia\|Juvenile Myelomonocytic Leukemia\|Myelodysplastic Syndrome	June 2, 2015	Phase 2
NCT01522976	National Cancer Institute (NCI)	Chronic Myelomonocytic Leukemia\|Chronic Myelomonocytic Leukemia-1\|Chronic Myelomonocytic Leukemia-2\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts\|Myelodysplastic Syndrome With Excess Blasts-1\|Myelodysplastic Syndrome With Excess Blasts-2	March 1, 2012	Phase 2
NCT04742101	Institut de Recherches Internationales Servier\|ADIR, a Servier Group company\|Servier	Acute Myeloid Leukemia	March 10, 2021	Phase 1\|Phase 2
NCT00351975	National Cancer Institute (NCI)	Accelerated Phase of Disease\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL\|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Blastic Phase\|Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia\|Previously Treated Myelodysplastic Syndrome\|Primary Myelofibrosis\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Disease\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndrome	June 2006	Phase 1
NCT04578600	Joseph Tuscano\|National Cancer Institute (NCI)\|Celgene\|University of California, Davis	Indolent B-Cell Non-Hodgkin Lymphoma\|Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma\|Recurrent Follicular Lymphoma\|Recurrent Hairy Cell Leukemia\|Recurrent Lymphoplasmacytic Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Mucosa-Associated Lymphoid Tissue Lymphoma\|Refractory Follicular Lymphoma\|Refractory Hairy Cell Leukemia\|Refractory Lymphoplasmacytic Lymphoma\|Refractory Mantle Cell Lymphoma\|Refractory Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Small Lymphocytic Lymphoma	October 23, 2020	Phase 1
NCT04937166	Kahr Medical	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia	January 13, 2022	Phase 1
NCT04275518	Ascentage Pharma Group Inc.\|Suzhou Yasheng Pharmaceutical Co., Ltd.	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndromes (MDS)	July 6, 2020	Phase 1
NCT03466294	University of Colorado, Denver	Acute Myeloid Leukemia	May 15, 2018	Phase 2
NCT02610777	Millennium Pharmaceuticals, Inc.\|Takeda	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic\|Leukemia, Myeloid, Acute	April 14, 2016	Phase 2
NCT04891068	University of Illinois at Chicago	Breast Cancer Female\|Breast Cancer Invasive	January 10, 2022	Phase 2
NCT03268954	Takeda\|Takeda Development Center Americas, Inc.	Myelodysplastic Syndrome\|Leukemia, Myelomonocytic, Chronic\|Leukemia, Myeloid, Acute	November 28, 2017	Phase 3
NCT04172844	Medical College of Wisconsin	Acute Myelogenous Leukemia	January 13, 2020	Phase 1
NCT02752035	Astellas Pharma Global Development, Inc.\|Astellas Pharma Inc	Acute Myeloid Leukemia (AML)\|Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation	August 1, 2016	Phase 3
NCT05471700	Zhujiang Hospital	Leukemia, Myeloid, Acute	August 1, 2022	Phase 1\|Phase 2
NCT03113643	Dana-Farber Cancer Institute\|Stemline Therapeutics, Inc.	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Blastic Plasmacytoid Dendritic Cell Neoplasm	June 26, 2017	Phase 1
NCT04480125	Ruijin Hospital	Peripheral T-cell Lymphoma	June 20, 2020	Phase 2
NCT04905407	Syros Pharmaceuticals	Acute Myeloid Leukemia	August 26, 2021	Phase 2
NCT02343939	Gilead Sciences	Acute Myeloid Leukemia	July 1, 2015	Phase 1\|Phase 2
NCT02587598	Incyte Corporation	Solid Tumors	December 29, 2015	Phase 1\|Phase 2
NCT03483948	Hutchison Medipharma Limited\|Hutchmed	Acute Myeloid Leukemia	October 9, 2018	Phase 1
NCT04778397	Gilead Sciences	Acute Myeloid Leukemia	July 1, 2021	Phase 3
NCT02675452	Amgen	Relapsed or Refractory Multiple Myeloma\|Relapsed or Refractory Acute Myeloid Leukemia	June 13, 2016	Phase 1
NCT00387647	H. Lee Moffitt Cancer Center and Research Institute\|Celgene Corporation	Leukemia	August 2006	Phase 2
NCT05365035	M.D. Anderson Cancer Center	Myelodysplastic Syndromes\|Myeloproliferative Chronic Myelomonocytic Leukemia	September 23, 2022	Phase 2
NCT03151304	Helsinn Healthcare SA	Myelodysplastic Syndromes	June 1, 2017	Phase 2
NCT01121757	Duke University\|Celgene	Follicular Lymphoma\|Marginal Zone Lymphoma	April 2010	Phase 2
NCT04140487	M.D. Anderson Cancer Center	Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic+Myeloproliferative Neoplasm\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Myelodysplastic+Myeloproliferative Neoplasm	December 17, 2019	Phase 1\|Phase 2
NCT02203773	AbbVie\|Genentech, Inc.	Acute Myelogenous Leukemia\|Myelogenous Leukemia\|Treatment Naive AML	October 6, 2014	Phase 1
NCT02929498	GlaxoSmithKline\|Parexel	Myelodysplastic Syndrome\|Myelodysplastic Syndromes	July 31, 2017	Phase 1\|Phase 2
NCT04712942	University of Leipzig\|Millennium Pharmaceuticals, Inc.	Acute Myeloid Leukemia in Remission\|Myelodysplastic Syndromes\|Minimal Residual Disease	January 1, 2021	Phase 2
NCT03383575	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Celgene	Acute Myeloid Leukemia\|Blasts 20-30 Percent of Bone Marrow Nucleated Cells\|Chronic Myelomonocytic Leukemia\|IDH2 Gene Mutation\|Myelodysplastic Syndrome With Excess Blasts\|Recurrent High Risk Myelodysplastic Syndrome\|Refractory High Risk Myelodysplastic Syndrome	January 17, 2018	Phase 2
NCT01290302	American Regent, Inc.	Myelodysplastic Syndrome\|Myelofibrosis\|Chronic Myeloid Leukemia\|Chronic Lymphocytic Leukemia	October 2010	Phase 1
NCT02260440	Anuradha Krishnamurthy\|Merck Sharp & Dohme LLC\|University of Pittsburgh	Metastatic Colorectal Cancer	January 2015	Phase 2
NCT01957644	Boehringer Ingelheim	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	November 6, 2013	Phase 1
NCT00234000	Jonsson Comprehensive Cancer Center\|CTI BioPharma\|Celgene Corporation	Leukemia\|Myelodysplastic Syndromes	February 2007	Phase 1
NCT02038816	Sunnybrook Health Sciences Centre\|Novartis	Myelodysplastic Syndromes	March 2014	Phase 2
NCT03745716	Aprea Therapeutics	MDS	January 11, 2019	Phase 3
NCT02009436	Albert Einstein College of Medicine\|National Cancer Institute (NCI)	Recurrent Non-Small Cell Lung Carcinoma\|Stage IV Non-Small Cell Lung Cancer	February 9, 2015	Phase 1
NCT00384956	Washington University School of Medicine	Myelodysplastic Syndromes	August 2006	Phase 2
NCT03397173	Case Comprehensive Cancer Center	Myelodysplastic Syndromes\|Myeloproliferative Neoplasm\|Acute Myeloid Leukemia	March 16, 2018	Phase 2
NCT04161885	AbbVie	Acute Myeloid Leukemia (AML)\|Cancer	February 26, 2020	Phase 3
NCT00948064	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC\|Celgene Corporation	Leukemia	September 8, 2009	Phase 2
NCT01983969	M.D. Anderson Cancer Center	Advanced Cancers\|Lymphoma	November 7, 2013	Phase 1\|Phase 2
NCT00350818	M.D. Anderson Cancer Center\|Celgene Corporation	Myelodysplastic Syndrome\|Leukemia	October 2005	Phase 1
NCT00071799	Celgene	Myelodysplastic Syndromes	November 1, 2003	Phase 3
NCT02599649	M.D. Anderson Cancer Center\|Bristol-Myers Squibb	Leukemia	March 21, 2016	Phase 2
NCT01743859	University of Colorado, Denver\|Celgene	Acute Myeloid Leukemia	December 6, 2012	Phase 2
NCT01908387	Celgene Corporation\|Celgene	Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|Acute Myeloid Leukemia\|Multiple Myeloma\|Non-Hodgkin Lymphoma\|Hodgkin Lymphoma	July 2013	Phase 1
NCT04241549	Janssen Pharmaceutical K.K.\|argenx	Leukemia, Myeloid, Acute	March 25, 2020	Phase 1
NCT04264806	Janssen Research & Development, LLC\|argenx	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	May 6, 2021	Phase 2
NCT03238248	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)	Myelodysplastic Syndromes\|Myeloproliferative Neoplasm	August 7, 2017	Phase 2
NCT01074047	Celgene	Acute Myeloid Leukemia	June 1, 2010	Phase 3
NCT01202877	M.D. Anderson Cancer Center\|Novartis Pharmaceuticals\|Celgene Corporation	Leukemia	March 2011	Phase 1\|Phase 2
NCT01556477	Nordic MDS Group	Myelodysplastic Syndrome\|Acute Myelogenous Leukemia	March 2012	Phase 2
NCT04150887	Janssen Research & Development, LLC\|argenx	Leukemia, Myeloid, Acute	December 23, 2019	Phase 1
NCT01011283	Eisai Inc.	Myelodysplastic Syndromes	November 2009	Phase 4
NCT04160052	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Recurrent Myelodysplastic Syndrome\|Refractory Myelodysplastic Syndrome\|Therapy-Related Myelodysplastic Syndrome	October 1, 2019	Phase 1\|Phase 2
NCT04511975	Innovent Biologics (Suzhou) Co. Ltd.	MDS	August 24, 2020	Phase 1
NCT01105377	National Cancer Institute (NCI)	Recurrent Colon Cancer\|Recurrent Rectal Cancer\|Stage IV Colon Cancer\|Stage IV Rectal Cancer	April 2010	Phase 2
NCT02712905	Incyte Corporation	Solid Tumors and Hematologic Malignancy	May 5, 2016	Phase 1\|Phase 2
NCT00382590	M.D. Anderson Cancer Center	Acute Myelogenous Leukemia\|Myelodysplastic Syndrome\|Leukemia	August 2005	Phase 2
NCT04435691	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	July 28, 2020	Phase 1\|Phase 2
NCT03745352	National Cancer Institute (NCI)	Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	May 20, 2019	Phase 2
NCT01794169	Karolinska University Hospital\|Celgene Corporation	Acute Myeloid Leukemia	March 2013	Phase 2
NCT04803201	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Angioimmunoblastic T-cell Lymphoma\|Enteropathy-Associated T-Cell Lymphoma\|Follicular T-Cell Lymphoma\|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma\|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma\|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype\|Peripheral T-Cell Lymphoma, Not Otherwise Specified	July 30, 2021	Phase 2
NCT01180322	University of Ulm	Acute Myeloid Leukemia (AML)	November 2010	Phase 2
NCT02816021	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC\|Celgene	Melanoma and Other Malignant Neoplasms of Skin\|Metastatic Melanoma	February 14, 2017	Phase 2
NCT00381693	Mayo Clinic\|National Cancer Institute (NCI)	Chronic Myeloproliferative Disorders\|Secondary Myelofibrosis	August 2006	Phase 2
NCT00543582	Mirati Therapeutics Inc.	Hodgkin Lymphoma\|Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)	October 2007	Phase 2
NCT01812252	Fred Hutchinson Cancer Center	Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Myelodysplastic Syndrome\|Secondary Myelodysplastic Syndrome	April 2, 2013	Phase 2
NCT02096042	M.D. Anderson Cancer Center\|Seagen Inc.	Leukemia	April 2014	Phase 1\|Phase 2
NCT03699384	Memorial Sloan Kettering Cancer Center\|Pfizer	Acute Myeloid Leukemia (AML)\|Minimal Residual Disease	October 3, 2018	Phase 1\|Phase 2
NCT03978364	Shandong Provincial Hospital	Myelodysplastic Syndromes,Acute Myeloid Leukemia	June 1, 2019	Phase 3
NCT00666497	Mirati Therapeutics Inc.	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	June 2008	Phase 2
NCT02269280	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Leukemia	October 13, 2014	Phase 2
NCT00528983	Celgene	Myelodysplastic Syndromes (MDS)\|Chronic Myelomonocytic Leukemia (CMML)\|Acute Myelogenous Leukemia (AML)	September 11, 2007	Phase 1
NCT02159040	Novartis Pharmaceuticals\|Novartis	High Risk MDS	September 11, 2014	Phase 2
NCT04913922	Ludwig-Maximilians - University of Munich	Acute Myeloid Leukemia	May 5, 2021	Phase 2
NCT02397720	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Bilineal Leukemia\|Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	April 7, 2015	Phase 2
NCT05367401	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes\|Acute Myeloid Leukemia	December 20, 2024	Phase 1\|Phase 2
NCT01065129	Washington University School of Medicine	Myelodysplastic Syndromes	September 2, 2010	Phase 1
NCT05008666	Sun Yat-sen University	Safety and Efficacy	December 1, 2021	Phase 2
NCT04964505	Brian Jonas\|GlycoMimetics Incorporated\|National Cancer Institute (NCI)\|University of California, Davis	Acute Myeloid Leukemia	July 2, 2021	Phase 1
NCT01617226	University of Birmingham\|Leukemia Research Fund\|Celgene\|Merck Sharp & Dohme LLC	Leukemia, Myeloid, Acute	September 2012	Phase 2
NCT05559008	Ruijin Hospital	Peripheral T Cell Lymphoma	September 30, 2022	Phase 1\|Phase 2
NCT03164057	St. Jude Children´s Research Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	June 15, 2017	Phase 2
NCT00901537	Loma Linda University	Non-small Cell Lung Cancer\|Squamous Cell Carcinoma of the Head and Neck	February 2009	Phase 1
NCT00101179	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Leukemia\|Myelodysplastic Syndrome\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndrome	November 3, 2004	Phase 1
NCT01038635	M.D. Anderson Cancer Center\|Celgene	Leukemia	December 2009	Phase 1\|Phase 2
NCT01913951	Washington University School of Medicine\|Sunesis Pharmaceuticals	Myelodysplastic Syndromes	November 22, 2013	Phase 1
NCT03486353	Fujifilm Pharmaceuticals U.S.A., Inc.	Myelodysplastic Syndrome (MDS)	October 2019	Phase 2
NCT03194932	St. Jude Children´s Research Hospital\|Gateway for Cancer Research	Acute Myeloid Leukemia	July 11, 2017	Phase 1
NCT00887068	M.D. Anderson Cancer Center\|Celgene	Leukemia\|AML\|MDS	April 21, 2009	Phase 3
NCT01200004	M.D. Anderson Cancer Center\|Yukiguni Maitake Company Ltd.	Advanced Cancers	April 2012	Phase 1
NCT00529022	M.D. Anderson Cancer Center\|Celgene Corporation	Solid Tumors	August 2007	Phase 1
NCT01168219	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Adult Acute Megakaryoblastic Leukemia\|Adult Acute Monoblastic Leukemia\|Adult Acute Monocytic Leukemia\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With Maturation\|Adult Acute Myeloid Leukemia With Minimal Differentiation\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL\|Adult Acute Myeloid Leukemia Without Maturation\|Adult Acute Myelomonocytic Leukemia\|Adult Erythroleukemia\|Adult Pure Erythroid Leukemia\|Alkylating Agent-Related Acute Myeloid Leukemia\|de Novo Myelodysplastic Syndrome\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndrome	July 15, 2010	Phase 2
NCT03573024	University of Colorado, Denver\|AbbVie	Acute Myeloid Leukemia	November 14, 2018	Phase 2
NCT04493138	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Myeloproliferative Neoplasm\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Recurrent Myeloproliferative Neoplasm	July 21, 2020	Phase 1\|Phase 2
NCT03217838	AstraZeneca	Acute Myeloid Leukaemia	July 31, 2017	Phase 1
NCT04173533	University of Birmingham	Acute Myeloid Leukemia\|Myelodysplasia	June 14, 2019	Phase 3
NCT01636609	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|High Risk Myelodysplastic Syndrome	November 20, 2012	Phase 1
NCT00006019	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lung Cancer\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Prostate Cancer	May 2000	Phase 2
NCT02721875	Boehringer Ingelheim	Myelodysplastic Syndromes	April 28, 2016	Phase 1
NCT00721214	Virginia Commonwealth University\|Celgene Corporation	Myelodysplastic Syndrome	July 2008	Phase 2
NCT03338348	University of Ulm\|Sunesis Pharmaceuticals	Acute Myeloid Leukemia\|Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)	April 19, 2018	Phase 2
NCT01926587	Onconova Therapeutics, Inc.	Myelodysplastic Syndrome\|Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia	August 2013	Phase 1\|Phase 2
NCT02472691	Heinrich-Heine University, Duesseldorf\|Celgene Corporation	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	May 2015	Phase 2
NCT02985190	Groupe Francophone des Myelodysplasies\|Celgene	MDS\|Systemic Autoimmune Diseases	January 26, 2017	Phase 2
NCT02966782	AbbVie\|Celgene; Genentech, Inc.	Myelodysplastic Syndromes (MDS)	March 7, 2017	Phase 1
NCT03092674	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts-2	December 22, 2017	Phase 2\|Phase 3
NCT05048615	Hospital Universitario Dr. Jose E. Gonzalez	AML	July 26, 2021	Phase 2
NCT03683433	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Bilineal Leukemia\|Acute Biphenotypic Leukemia\|Chronic Myelomonocytic Leukemia\|IDH2 Gene Mutation\|Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	September 18, 2018	Phase 2
NCT00481273	Celgene	Myelodysplastic Syndromes	October 31, 2006
NCT01358734	Celgene	Acute Myeloid Leukemia\|Acute Myelogenous Leukemia	April 27, 2012	Phase 2
NCT03226418	University of Nebraska\|National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	July 7, 2017	Phase 2
NCT01301820	French Innovative Leukemia Organisation\|Celgene Corporation	Acute Myeloid Leukemia	January 2011	Phase 2
NCT00895934	National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	May 2009	Phase 1\|Phase 2
NCT01545947	Celgene	Carcinoma, Non-Small-Cell Lung\|Non-Small Cell Lung Cancer	May 1, 2012	Phase 1
NCT05317000	Barbara Burtness\|Yale University	Squamous Cell Carcinoma of Head and Neck	November 2022	Early Phase 1
NCT02281084	Celgene	Myelodysplastic Syndromes	July 6, 2015	Phase 2
NCT01873703	Helsinn Healthcare SA	Myelodysplastic Syndrome	June 2013	Phase 2
NCT00728520	Kansas City Veteran Affairs Medical Center	Acute Myeloid Leukemia\|Elderly	July 2008	Phase 2
NCT00313586	National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL\|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA\|Alkylating Agent-Related Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Previously Treated Myelodysplastic Syndrome\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndrome\|Untreated Adult Acute Myeloid Leukemia	August 2006	Phase 2
NCT01129180	Pierluigi Porcu\|Millennium Pharmaceuticals, Inc.\|Celgene Corporation\|Ohio State University Comprehensive Cancer Center	Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Hepatosplenic T-cell Lymphoma\|Peripheral T-cell Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Prolymphocytic Leukemia\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Small Intestine Lymphoma\|T-cell Large Granular Lymphocyte Leukemia	May 2010	Phase 1
NCT05075460	Peking Union Medical College Hospital	T-cell Lymphoma	October 1, 2021	Phase 3
NCT05209152	Amgen	Higher Risk Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia	November 7, 2022	Phase 1
NCT05379166	Uma Borate\|Ohio State University Comprehensive Cancer Center	Secondary Myelodysplastic Syndrome\|Therapy-Related Myelodysplastic Syndrome	June 30, 2022	Phase 2
NCT05361057	Institute of Hematology & Blood Diseases Hospital	Acute Myeloid Leukemia\|Measurable Disease	May 1, 2022	Phase 2
NCT01700673	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	June 2013	Phase 2
NCT04905810	Brian Jonas\|AbbVie\|National Cancer Institute (NCI)\|University of California, Davis	Acute Myeloid Leukemia\|Recurrent Acute Myeloid Leukemia	February 9, 2022	Phase 2
NCT04227847	Seagen Inc.	Myelodyspastic Syndrome\|Acute Myeloid Leukemia	August 7, 2020	Phase 1
NCT01720225	M.D. Anderson Cancer Center	Leukemia	November 6, 2012	Phase 2
NCT00336063	National Cancer Institute (NCI)	Adult Nasal Type Extranodal NK+T-Cell Lymphoma\|Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma\|Recurrent Nasopharyngeal Undifferentiated Carcinoma\|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7\|Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7	March 3, 2006	Phase 1
NCT00005639	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Lymphoma\|Small Intestine Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	March 2000	Phase 1
NCT01757535	Celgene	Leukemia, Myeloid, Acute	April 24, 2013	Phase 3
NCT00005598	University of Michigan Rogel Cancer Center\|National Cancer Institute (NCI)	Myelodysplastic Syndromes	October 2000	Phase 2
NCT04866056	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Myelodysplastic Syndromes\|Myeloproliferative Neoplasms\|Myelofibrosis	January 2022	Phase 1\|Phase 2
NCT04248595	Ge Zheng\|Zhongda Hospital	Acute Myeloid Leukemia	December 1, 2019	Phase 2
NCT00495547	PETHEMA Foundation\|Roche Pharma AG\|Celgene Corporation	Myelodysplastic Syndrome	February 2009	Phase 2
NCT05292664	Andrew E. Place\|AbbVie\|Servier\|Children´s Cancer Research Fund\|University of Colorado, Denver\|Boston Children´s Hospital\|Dana-Farber Cancer Institute	Myelodysplastic Syndromes, de Novo\|Myelodysplastic Syndromes, Secondary\|Myelodysplastic Syndromes, Previously Treated\|Treatment-Related Acute Myeloid Leukemia\|Therapy-Related Myelodysplastic Syndrome\|Acute Lymphoblastic Leukemia, in Relapse\|Acute Lymphoblastic Leukemia With Failed Remission\|Lymphoblastic Lymphoma, in Relapse\|Lymphoblastic Lymphoma, Refractory\|Acute Leukemia of Ambiguous Lineage in Relapse\|Acute Leukemia of Ambiguous Lineage Not Having Achieved Remission	October 2022	Phase 1
NCT00569010	M.D. Anderson Cancer Center\|Celgene Corporation	Acute Myelogenous Leukemia\|Myelodysplastic Syndrome\|Leukemia	December 2005	Phase 1\|Phase 2
NCT01814826	Millennium Pharmaceuticals, Inc.\|Takeda	Acute Myelogenous Leukemia	April 10, 2013	Phase 1
NCT04401748	AbbVie\|Genentech, Inc.	Myelodysplastic Syndrome (MDS)	September 10, 2020	Phase 3
NCT01993641	Helsinn Healthcare SA	Myelodysplastic Syndrome\|MDS	December 2013	Phase 2
NCT04505995	Air Force Military Medical University, China\|Qilu Hospital of Shandong University\|Taian City Central Hospital\|The Affiliated Hospital of Qingdao University\|The Second Hospital of Hebei Medical University\|Children´s Hospital of Hebei Province	JMML	January 1, 2020	Not Applicable
NCT01260714	National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia\|Adult Acute Monoblastic Leukemia\|Adult Acute Monocytic Leukemia\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With Maturation\|Adult Acute Myeloid Leukemia With Minimal Differentiation\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL\|Adult Acute Myeloid Leukemia Without Maturation\|Adult Acute Myelomonocytic Leukemia\|Adult Erythroleukemia\|Adult Pure Erythroid Leukemia\|Alkylating Agent-Related Acute Myeloid Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	December 2010	Phase 1
NCT00384839	US Oncology Research\|Celgene Corporation\|University of Southern California	Prostate Cancer	April 2006	Phase 2
NCT04146038	Rutgers, The State University of New Jersey\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia\|Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells\|Myelodysplastic Syndrome\|Myeloproliferative Neoplasm\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia	October 26, 2020	Phase 2
NCT02940483	The University of Texas Health Science Center, Houston	Brain Tumor Recurrent	February 1, 2017	Early Phase 1
NCT01015352	Groupe Francophone des Myelodysplasies\|Celgene Corporation\|Roche Pharma AG	Myelodysplastic Syndromes	February 2009	Phase 2
NCT03701295	National Cancer Institute (NCI)	Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL\|Leukemia Cutis\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	January 16, 2019	Phase 1\|Phase 2
NCT05183035	LLS PedAL Initiative, LLC\|Princess Maxima Center for Pediatric Oncology (European Sponsor)\|AbbVie\|Roche-Genentech\|EuPAL	Acute Myeloid Leukemia	October 1, 2022	Phase 3
NCT03684811	Forma Therapeutics, Inc.	Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)\|Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)\|Cohort 3a and 3b: Chondrosarcoma\|Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma\|Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations	November 1, 2018	Phase 1\|Phase 2
NCT01599325	Celgene	Myelodysplastic Syndrome (MDS)	July 24, 2012	Phase 2
NCT01235117	University of Leeds\|National Cancer Institute (NCI)	Leukemia	January 2010	Phase 2
NCT00102687	Celgene	Myelodysplastic Syndromes	January 1, 2005	Phase 2
NCT01048034	Nordic MDS Group	Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia	January 2010	Phase 2
NCT03628209	H. Lee Moffitt Cancer Center and Research Institute\|Bristol-Myers Squibb	Osteosarcoma\|Osteosarcoma in Children\|Osteosarcoma Recurrent\|Sarcoma	October 3, 2019	Phase 1\|Phase 2
NCT02719574	Forma Therapeutics, Inc.	Acute Myeloid Leukemia\|Acute Myelogenous Leukemia\|Myelodysplastic Syndrome	April 2016	Phase 1\|Phase 2
NCT04912063	AbbVie	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	June 25, 2021	Phase 1
NCT03709576	Milton S. Hershey Medical Center\|Millennium Pharmaceuticals, Inc.\|Takeda	Acute Myeloid Leukemia (AML)	July 18, 2018	Phase 2
NCT02399917	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	April 20, 2015	Phase 2
NCT01652781	Seoul St. Mary´s Hospital\|Celgene Corporation	Myelodysplastic Syndrome	March 2012	Phase 2
NCT01386346	Weill Medical College of Cornell University\|Celgene Corporation	Esophageal Cancer\|Malignant Neoplasm of Cardio-esophageal Junction of Stomach	June 2011	Phase 1
NCT00652626	Celgene	MDS\|AML\|Solid Tumors\|Multiple Myeloma\|Non-Hodgkin´s Lymphoma\|Hodgkin´s Disease	November 1, 2008	Phase 1
NCT00118196	Medical University of South Carolina	Leukemia\|Myelodysplastic Syndromes	April 2005	Phase 2
NCT02201329	Boehringer Ingelheim	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	August 2014	Phase 1
NCT02750254	Washington University School of Medicine	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Acute Lymphocytic Leukemia	June 27, 2016	Phase 1
NCT04958486	The University of Texas Health Science Center, Houston	Fossa Ependymoma	July 8, 2021	Early Phase 1
NCT00326170	M.D. Anderson Cancer Center\|Celgene Corporation	Myelodysplastic Syndrome\|Acute Myelogenous Leukemia	July 2005	Phase 2
NCT01039155	National Cancer Institute (NCI)	Adult Solid Neoplasm\|Hematopoietic and Lymphoid Cell Neoplasm	December 2009	Phase 1
NCT02942290	AbbVie\|Genentech, Inc.	Myelodysplastic Syndromes (MDS)	January 12, 2017	Phase 1
NCT05376111	The First Affiliated Hospital of Soochow University\|Jining Medical University\|The Second People´s Hospital of Huai´an\|First Affiliated Hospital Bengbu Medical College\|Northern Jiangsu Province People´s Hospital\|Affiliated Hospital of Nantong University\|Suzhou Hospital of Traditional Chinese Medicine	T-cell Acute Lymphoblastic Leukemia\|Recruiting	April 1, 2022	Phase 2
NCT01305135	Groupe Francophone des Myelodysplasies	High Grade Myelodysplastic Syndrome Lesions	December 30, 2010	Phase 1\|Phase 2
NCT04778410	Gilead Sciences	Myeloid Malignancies	June 28, 2021	Phase 2
NCT00443261	University of Kansas Medical Center\|Celgene Corporation	Squamous Cell Carcinoma	February 2007	Phase 1
NCT05179213	Peking Union Medical College Hospital\|Beijing Longfu Hospital	Angioimmunoblastic T-cell Lymphoma	January 1, 2022	Phase 2
NCT05168202	Bristol-Myers Squibb	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes	January 19, 2022	Phase 1
NCT01155583	Case Comprehensive Cancer Center	Refractory Multiple Myeloma	June 2010	Phase 1\|Phase 2
NCT01462578	Technische Universität Dresden	Acute Myelocytic Leukemia\|Myelodysplastic Syndrome	September 2011	Phase 2
NCT01488565	Peter MacCallum Cancer Centre, Australia\|GlaxoSmithKline\|Celgene Corporation	Myelodysplastic Syndromes (MDS)\|Acute Myeloid Leukaemia (AML)	December 2010	Phase 2
NCT00352001	Mikkael Sekeres MD\|National Cancer Institute (NCI)\|Case Comprehensive Cancer Center	Leukemia\|Myelodysplastic Syndromes	May 2006	Phase 1\|Phase 2
NCT01193517	M.D. Anderson Cancer Center\|Celgene	Colorectal Cancer	August 2010	Phase 1\|Phase 2
NCT04266301	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	June 8, 2020	Phase 3
NCT03769532	Technische Universität Dresden\|Merck Sharp & Dohme LLC	Acute Myeloid Leukemia	August 21, 2019	Phase 2
NCT00748553	University of Utah\|Celgene Corporation	Advanced or Metastatic Solid Tumors\|Advanced or Metastatic Breast Cancer	September 2008	Phase 1\|Phase 2
NCT01053806	Tel-Aviv Sourasky Medical Center	Myelodysplastic Syndrome	August 2011	Phase 2
NCT04501120	Ascentage Pharma Group Inc.\|Suzhou Yasheng Pharmaceutical Co., Ltd.	Relapsed+Refractory Acute Myeloid Leukaemia\|Myeloid Malignancy	September 28, 2020	Phase 1\|Phase 2
NCT01747499	Washington University School of Medicine\|The Foundation for Barnes-Jewish Hospital\|National Cancer Institute (NCI)\|National Institutes of Health (NIH)	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	April 15, 2013	Phase 1\|Phase 2
NCT05144243	AbbVie\|Genentech, Inc.	Acute Myeloid Leukemia (AML)	January 6, 2022	Phase 4
NCT02018926	Mirati Therapeutics Inc.	Myelodysplastic Syndrome	December 2013	Phase 1\|Phase 2
NCT05197426	Bristol-Myers Squibb	Acute Myeloid Leukemia	January 17, 2022	Phase 2
NCT03588078	Groupe Francophone des Myelodysplasies\|Aprea Therapeutics	Myelodysplastic Syndrome With Gene Mutation\|Acute Myeloid Leukemia With Gene Mutations\|Myeloproliferative Neoplasm\|Chronic Myelomonocytic Leukemia	September 15, 2018	Phase 1\|Phase 2
NCT00398450	University of California, San Diego\|National Cancer Institute (NCI)	Melanoma (Skin)	February 2006	Phase 1
NCT05053425	LanZhou University	Acute Myeloid Leukemia	October 20, 2021	Not Applicable
NCT00413478	M.D. Anderson Cancer Center\|Celgene Corporation	Chronic Lymphocytic Leukemia\|Leukemia	September 2006	Phase 2
NCT03564873	University of Colorado, Denver	High Grade Myelodysplastic Syndromes	September 17, 2018	Phase 1\|Phase 2
NCT04980885	Akeso	Acute Myeloid Leukemia	August 13, 2021	Phase 1\|Phase 2
NCT04023526	Janssen Research & Development, LLC\|argenx	Leukemia, Myeloid, Acute	July 29, 2019	Phase 2
NCT02038777	Pfizer	Acute Myeloid Leukemia	March 25, 2014	Phase 1
NCT05476770	Therapeutic Advances in Childhood Leukemia Consortium	Hematologic Malignancy\|AML\|ALL\|BPDCN\|MDS\|Lymphoblastic Lymphoma\|Lymphoma, B-Cell\|Lymphoma, T-Cell\|Hodgkin Lymphoma\|Mixed Phenotype Acute Leukemia\|Acute Undifferentiated Leukemia	November 11, 2022	Phase 1
NCT00379912	Larry Cripe, MD\|Celgene Corporation\|Ortho Biotech Clinical Affairs, L.L.C.\|Walther Cancer Institute\|Hoosier Cancer Research Network	Myelodysplastic Syndromes	September 2006	Phase 2
NCT02497404	Weill Medical College of Cornell University	Leukemia, Erythroblastic, Acute\|Myelodysplastic Syndromes	February 13, 2015	Phase 2
NCT04102020	AbbVie\|Roche-Genentech	Acute Myeloid Leukemia (AML)	March 26, 2020	Phase 3
NCT04553692	IGM Biosciences, Inc.	Solid Tumor\|Colorectal Cancer\|Non Hodgkin Lymphoma\|Sarcoma\|Chondrosarcoma\|Small Lymphocytic Lymphoma\|Chronic Lymphocytic Leukemia\|Acute Myeloid Leukemia	September 23, 2020	Phase 1
NCT05325099	National Taiwan University Hospital	Acute Kidney Disease	June 30, 2022	Phase 1\|Phase 2
NCT01050790	Virginia Commonwealth University\|National Cancer Institute (NCI)\|Celgene Corporation	Multiple Myeloma	January 2010	Not Applicable
NCT05457361	Nanfang Hospital of Southern Medical University\|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University\|Zhongshan People´s Hospital, Guangdong, China\|Shenzhen Hospital of Southern Medical University\|Peking University Shenzhen Hospital\|Shenzhen Second People´s Hospital\|The Seventh Affiliated Hospital of Sun Yat-sen University\|Southern Medical University, China\|First People´s Hospital of Chenzhou\|The Affiliated Hospital of Qingdao University\|First Affiliated Hospital of Guangxi Medical University	Venetoclax Combined With Azacitidine Plus Homoharringtonine\|Venetoclax Combined With Azacitidine	March 1, 2022	Phase 3
NCT04068597	CellCentric Ltd.	Haematological Malignancy\|Acute Myeloid Leukemia\|Non Hodgkin Lymphoma\|Multiple Myeloma\|Higher-risk Myelodysplastic Syndrome	August 9, 2019	Phase 1\|Phase 2
NCT05162976	City of Hope Medical Center\|National Cancer Institute (NCI)	Recurrent Classic Hodgkin Lymphoma\|Refractory Classic Hodgkin Lymphoma	January 3, 2022	Phase 1
NCT03513484	Northwestern University\|Robert H. Lurie Cancer Center\|Boehringer Ingelheim\|National Cancer Institute (NCI)	Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A\|Fibroblast Growth Factor Basic Form Measurement\|FLT3 Internal Tandem Duplication\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	November 14, 2018	Phase 1
NCT05428969	Faron Pharmaceuticals Ltd	Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndromes\|Relapsed+Refractory AML	June 2, 2022	Phase 1\|Phase 2
NCT01718366	Groupe Francophone des Myelodysplasies\|Novartis	MDS	February 2013	Phase 1\|Phase 2
NCT03151408	Helsinn Healthcare SA\|Clinipace Worldwide	Acute Myeloid Leukemia	June 23, 2017	Phase 3
NCT04752163	M.D. Anderson Cancer Center	Hematopoietic and Lymphoid Cell Neoplasm\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Lymphoblastic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Myelodysplastic Syndrome	March 25, 2021	Phase 1\|Phase 2
NCT01110473	AbbVie (prior sponsor, Abbott)\|AbbVie	Acute Lymphoblastic Leukemia\|Acute Myelogenous Leukemia\|B-cell Chronic Lymphocytic Leukemia\|Chronic Myelogenous Leukemia\|Myelodysplasia	April 2010	Phase 1
NCT00454480	The University of New South Wales\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	August 2006	Phase 2\|Phase 3
NCT04313881	Gilead Sciences	Myelodysplastic Syndromes	September 9, 2020	Phase 3
NCT03813147	National Cancer Institute (NCI)\|Children´s Oncology Group	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory Myelodysplastic Syndrome	May 1, 2019	Phase 1
NCT02530463	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndrome\|Recurrent Myelodysplastic Syndrome	September 8, 2015	Phase 2
NCT05182957	The First Affiliated Hospital of Soochow University	Relapsed+Refractory Peripheral T-cell Lymphoma	December 14, 2021	Phase 2
NCT04257448	GWT-TUD GmbH\|Celgene\|AstraZeneca	Pancreas Cancer\|Pancreatic Adenocarcinoma\|Pancreatic Ductal Adenocarcinoma	May 25, 2020	Phase 1\|Phase 2
NCT05554419	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	February 28, 2023	Phase 2
NCT03066648	Novartis Pharmaceuticals\|Novartis	Leukemia\|Leukemia, Myeloid\|Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes\|Preleukemia\|Bone Marrow Diseases\|Hematologic Diseases\|Chronic Myelomonocytic Leukemia	July 6, 2017	Phase 1
NCT03390296	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	December 27, 2017	Phase 1\|Phase 2
NCT05469737	Bristol-Myers Squibb	Myelodysplastic Syndromes	November 30, 2022	Phase 2\|Phase 3
NCT03072043	H. Lee Moffitt Cancer Center and Research Institute\|Aprea Therapeutics	Myelodysplastic Syndrome\|Acute Myeloid Leukemia\|Myeloproliferative Neoplasm\|Chronic Myelomonocytic Leukemia	May 18, 2017	Phase 1\|Phase 2
NCT00923234	Technische Universität Dresden\|Celgene Corporation	Myelodysplastic Syndromes\|Acute Myelogenous Leukemia	June 2009	Phase 1
NCT05155709	Novartis Pharmaceuticals\|Novartis	Acute Myeloid Leukemia	May 17, 2022	Phase 1\|Phase 2
NCT02323139	Groupe Francophone des Myelodysplasies\|Novartis	MDS	February 10, 2015	Phase 1
NCT02835794	University of Florida\|Teva Pharmaceutical Industries, Ltd.	Myelodysplastic Syndromes	August 2016	Phase 1\|Phase 2
NCT01442714	Stanford University\|Celgene Corporation	Leukemia\|Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndromes (MDS)	August 2011	Phase 2
NCT03284593	University Hospital, Toulouse	Acute Myeloid Leukemia	December 2014
NCT04230564	Pfizer	Leukemia, Myeloid, Acute	October 31, 2020
NCT03248479	Gilead Sciences	Hematological Malignancies	September 8, 2017	Phase 1
NCT04184505	Gruppo Italiano Malattie EMatologiche dell´Adulto	High-risk MDS	November 27, 2020	Phase 3
NCT00946647	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|Acute Myeloid Leukemia	December 2, 2009	Phase 1\|Phase 2
NCT04485052	Innovent Biologics (Suzhou) Co. Ltd.	Acute Myeloid Leukemia	September 25, 2020	Phase 1\|Phase 2
NCT04062266	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Genentech, Inc.	Acute Myeloid Leukemia in Remission\|FLT3 Gene Mutation\|Hematologic and Lymphocytic Disorder\|Acute Myeloid Leukemia\|Minimal Residual Disease Persistence\|Therapy-Related Acute Myeloid Leukemia	September 13, 2019	Phase 2
NCT03843528	Johns Hopkins All Children´s Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Mixed Phenotype Acute Leukemia\|Juvenile Myelomonocytic Leukemia	May 1, 2019	Phase 1
NCT03530683	Pfizer	Lymphoma\|Multiple Myeloma\|Acute Myeloid Leukemia\|Diffuse Large B-Cell Lymphoma	June 7, 2018	Phase 1
NCT05226455	Groupe Francophone des Myelodysplasies\|AbbVie	MDS\|AML	September 1, 2022	Phase 1\|Phase 2
NCT05442216	Joshua Zeidner\|Stemline Therapeutics, Inc.\|University of North Carolina, Chapel Hill\|Hoosier Cancer Research Network	Acute Myeloid Leukemia	December 2022	Phase 2
NCT01349959	National Cancer Institute (NCI)	Male Breast Carcinoma\|Recurrent Breast Carcinoma\|Stage IIIC Breast Cancer AJCC v7\|Stage IV Breast Cancer AJCC v6 and v7\|Triple-Negative Breast Carcinoma	April 21, 2011	Phase 2
NCT04336982	Celgene\|AbbVie	Leukemia, Myeloid, Acute	August 5, 2020	Phase 1\|Phase 2
NCT02447666	Celgene	Myelodysplastic Syndrome\|Leukemia, Myelomonocytic, Juvenile	September 15, 2015	Phase 2
NCT05305859	The First Affiliated Hospital of Xiamen University\|Fujian Provincial Hospital\|Fujian Cancer Hospital\|Zhangzhou manicipal hospital of Fujian Province\|Jieyang People´s Hospital\|Dongguan People´s Hospital\|Huizhou Municipal Central Hospital	Leukemia, Myeloid, Acute\|Relapsed Adult AML\|Refractory Leukemia	April 1, 2022	Phase 2
NCT03493646	Kirby Institute\|Celgene	Myelodysplastic Syndromes\|Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia	June 18, 2018	Phase 2
NCT02954653	Pfizer	Acute Myeloid Leukemia	November 28, 2016	Phase 1
NCT05079230	Gilead Sciences	Acute Myeloid Leukemia	July 7, 2022	Phase 3
NCT02828358	National Cancer Institute (NCI)	Acute Leukemia of Ambiguous Lineage\|B Acute Lymphoblastic Leukemia\|Mixed Phenotype Acute Leukemia	March 27, 2017	Phase 2
NCT02543879	Forma Therapeutics, Inc.	Acute Myeloid Leukemia\|Acute Myelogenous Leukemia\|Myelodysplastic Syndrome\|Non-Hodgkin Lymphoma	September 2015	Phase 1
NCT05048498	Nanexa AB\|Uppsala University	Myelodysplastic Syndromes (MDS)\|Chronic Myelomonocytic Leukemia (CMML)\|Acute Myeloid Leukemia (AML)	April 27, 2021	Phase 1
NCT01324960	Groupe Francophone des Myelodysplasies\|EpiCept Corporation	Myelodysplastic Syndromes	March 2011	Phase 1\|Phase 2
NCT04150029	Novartis Pharmaceuticals\|Novartis	Acute Myeloid Leukemia	September 1, 2020	Phase 2
NCT04518345	Uma Borate\|Sumitomo Pharma Oncology, Inc.\|Ohio State University Comprehensive Cancer Center	Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	November 5, 2020	Phase 1\|Phase 2
NCT05175508	The First Affiliated Hospital of Soochow University	AML\|MDS\|Old Age; Debility\|Hematologic Cancer	May 1, 2021	Phase 2\|Phase 3
NCT04086264	ImmunoGen, Inc.\|Jazz Pharmaceuticals	Acute Myeloid Leukemia	November 6, 2019	Phase 1\|Phase 2
NCT03259516	St. Petersburg State Pavlov Medical University	Myelodysplastic Syndromes	May 25, 2017	Phase 1\|Phase 2
NCT04809181	First Affiliated Hospital of Zhejiang University\|Second Affiliated Hospital, School of Medicine, Zhejiang University\|Zhejiang Provincial People´s Hospital\|The First Affiliated Hospital of Zhejiang Chinese Medical University\|Sir Run Run Shaw Hospital\|First Affiliated Hospital of Wenzhou Medical University\|Ningbo No. 1 Hospital\|Yinzhou Hospital Affiliated to Medical School of Ningbo University\|Jinhua Central Hospital\|Taizhou Hospital\|Union hospital of Fujian Medical University\|Xiangya Hospital of Central South University	Hematologic Malignancy\|Stem Cell Transplant Complications	March 19, 2021	Phase 2
NCT03264404	Rachael A Safyan, MD\|Columbia University	Pancreas Cancer	October 1, 2017	Phase 2
NCT02807558	Syros Pharmaceuticals	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	August 2016	Phase 2
NCT01571648	Celgene	Myelodysplastic Syndromes	April 1, 2012	Phase 1
NCT02951156	Pfizer\|EMD Serono	Diffuse Large B-Cell Lymphoma	December 16, 2016	Phase 3
NCT00439673	Gruppo Italiano Malattie EMatologiche dell´Adulto	Myelodysplastic Syndromes	May 2007	Phase 2
NCT05042531	LanZhou University\|Beijing Health Alliance Charitable Foundation	Acute Myeloid Leukemia	November 13, 2021	Not Applicable
NCT02158936	Novartis Pharmaceuticals\|Novartis	Thrombocytopaenia	June 10, 2014	Phase 3
NCT04687761	PETHEMA Foundation	Leukemia, Myeloid, Acute\|De Novo\|Age More 60yr	November 4, 2020	Phase 1\|Phase 2
NCT04284787	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	August 3, 2020	Phase 2
NCT03932318	Actinium Pharmaceuticals	Acute Myeloid Leukemia\|Relapsed Adult AML	March 2023	Phase 1\|Phase 2
NCT01254890	M.D. Anderson Cancer Center\|Bayer\|Onyx Therapeutics, Inc.\|Celgene	Leukemia	January 2011	Phase 1\|Phase 2
NCT04799275	National Cancer Institute (NCI)	Ann Arbor Stage III Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma\|Diffuse Large B-Cell Lymphoma Activated B-Cell Type\|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation\|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type\|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|Grade 3b Follicular Lymphoma\|HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|Intravascular Large B-Cell Lymphoma\|Lymphoplasmacytic Lymphoma\|Nodular Lymphocyte Predominant Hodgkin Lymphoma\|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type\|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma\|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma\|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma	March 19, 2021	Phase 2\|Phase 3
NCT00118287	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	de Novo Myelodysplastic Syndromes\|Previously Treated Myelodysplastic Syndromes\|Secondary Myelodysplastic Syndromes	April 2005	Phase 1\|Phase 2
NCT00890929	Stanford University\|Celgene Corporation	Acute Myeloid Leukemia (AML)\|Adult Acute Myeloblastic Leukemia	April 2009	Phase 1\|Phase 2
NCT02782468	Millennium Pharmaceuticals, Inc.\|Takeda	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes	May 16, 2016	Phase 1
NCT05140811	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.\|Institute of Hematology & Blood Diseases Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	January 1, 2022	Phase 1\|Phase 2
NCT04484363	Takeda	Myelodysplastic Syndromes
NCT01886573	National Cancer Institute (NCI)	Stage IA Non-Small Cell Lung Carcinoma\|Stage IB Non-Small Cell Lung Carcinoma\|Stage IIA Non-Small Cell Lung Carcinoma\|Stage IIB Non-Small Cell Lung Carcinoma\|Stage IIIA Non-Small Cell Lung Cancer	June 2013	Phase 1
NCT04748848	Celgene	Leukemia, Myeloid	October 14, 2021	Phase 1
NCT03593018	The Lymphoma Academic Research Organisation\|Celgene	Relapsed Angioimmunoblastic T-Cell Lymphoma\|Refractory Angioimmunoblastic T-cell Lymphoma	November 9, 2018	Phase 3
NCT04755244	ALX Oncology Inc.	Acute Myeloid Leukemia\|AML, Adult	May 5, 2021	Phase 1\|Phase 2
NCT05401097	Alice Mims\|Ohio State University Comprehensive Cancer Center	Acute Myeloid Leukemia	August 1, 2022	Phase 2
NCT00842582	Loyola University\|Celgene Corporation	Ovarian Cancer	February 2009	Phase 1
NCT03173248	Institut de Recherches Internationales Servier\|Servier	Newly Diagnosed Acute Myeloid Leukemia (AML)\|Untreated AML\|AML Arising From Myelodysplastic Syndrome (MDS)\|Leukemia, Myeloid, Acute	June 26, 2017	Phase 3
NCT05141682	Jonathan Brammer\|Bristol-Myers Squibb\|Ohio State University Comprehensive Cancer Center	T-Cell Large Granular Lymphocyte Leukemia	May 1, 2022	Phase 1\|Phase 2
NCT02204020	University of Pittsburgh	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	April 2015	Phase 2
NCT05074355	University Health Network, Toronto	Myeloproliferative Neoplasm	May 16, 2022	Phase 2
NCT03572530	The University of Texas Health Science Center, Houston	Recurrent Ependymoma	February 8, 2019	Phase 1
NCT05586074	Sunshine Lake Pharma Co., Ltd.	Leukemia, Acute Myeloid (AML)	November 28, 2022	Phase 3
NCT01088373	Groupe Francophone des Myelodysplasies\|Celgene	Myelodysplastic Syndromes	March 25, 2010	Phase 2
NCT05566054	The First Affiliated Hospital of Soochow University\|Jining Medical University\|The Second People´s Hospital of Huai´an\|First Affiliated Hospital Bengbu Medical College\|Northern Jiangsu Province People´s Hospital\|Affiliated Hospital of Nantong University\|Suzhou Hospital of Traditional Chinese Medicine\|Taizhou University	Acute Monocytic Leukemia\|Newly Diagnosed	March 1, 2022	Phase 2
NCT04216355	Fujian Medical University	MDS-EB	January 2020	Phase 2\|Phase 3
NCT04629443	Institut de Recherches Internationales Servier\|ADIR, a Servier Group company\|Servier	Acute Myeloid Leukaemia	February 17, 2021	Phase 1\|Phase 2
NCT01207726	National Cancer Institute (NCI)	Stage IA Non-Small Cell Lung Carcinoma\|Stage IB Non-Small Cell Lung Carcinoma	September 2010	Phase 2
NCT04602273	Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias\|Hospital Son Llatzer\|Germans Trias i Pujol Hospital\|Celgene Corporation	Myelodysplastic Syndromes	December 12, 2016
NCT00569660	M.D. Anderson Cancer Center\|Celgene Corporation	Myelofibrosis	June 2005	Phase 2
NCT03703375	Celgene	Lymphoma, T-Cell	November 6, 2018	Phase 3
NCT03047993	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia With Multilineage Dysplasia\|Blasts 20-30 Percent of Bone Marrow Nucleated Cells\|Blasts 20-30 Percent of Peripheral Blood White Cells\|Chronic Myelomonocytic Leukemia\|High Risk Myelodysplastic Syndrome\|IPSS Risk Category Intermediate-2\|Myelodysplastic Syndrome	November 15, 2017	Phase 1\|Phase 2
NCT04078399	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	HSCT\|Efficacy and Safety	August 28, 2019	Not Applicable
NCT03941496	Andrew Dinardo\|Bristol-Myers Squibb\|Baylor College of Medicine	Tuberculosis, Pulmonary	September 2022	Phase 1\|Phase 2
NCT00004062	Lucille P. Markey Cancer Center at University of Kentucky\|National Cancer Institute (NCI)	Head and Neck Cancer	July 1999	Phase 1
NCT02677922	Celgene	Leukemia, Myeloid, Acute	June 3, 2016	Phase 1\|Phase 2
NCT02367456	Pfizer	Myelodysplastic Syndrome\|Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia	April 28, 2015	Phase 1
NCT01379274	Rush University Medical Center\|Celgene Corporation	MDS	January 2011	Phase 2
NCT04842604	Pfizer	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia	May 17, 2021	Phase 3
NCT04878432	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndrome (MDS)	March 17, 2022	Phase 2
NCT04771130	BeiGene	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasm	May 24, 2021	Phase 1\|Phase 2
NCT05554393	National Cancer Institute (NCI)	Acute Myeloid Leukemia	February 28, 2023	Phase 2
NCT00412919	Bayside Health	Multiple Myeloma	December 2006	Phase 2
NCT01892371	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	FLT3 Gene Mutation Negative\|FLT3 Internal Tandem Duplication Positive\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Myelodysplastic Syndrome	November 12, 2013	Phase 1\|Phase 2
NCT02993523	AbbVie\|Genentech, Inc.	Acute Myeloid Leukemia (AML)	February 2, 2017	Phase 3
NCT02750995	Daniel El Fassi\|Technical University of Denmark\|Herlev Hospital	Myelodysplastic Syndrome\|Acute Myeloid Leukemia	April 2016	Phase 1
NCT04623216	Novartis Pharmaceuticals\|Novartis	Acute Myeloid Leukemia	September 14, 2021	Phase 1\|Phase 2
NCT03613532	Jacqueline Garcia, MD\|National Institutes of Health (NIH)\|Dana-Farber Cancer Institute	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)\|Chronic Myelomonocytic Leukemia (CMML)\|MDS+Myeloproliferative Neoplasm-unclassifiable (MDS+MPN-unclassifiable)\|Hematopoietic Stem Cell Transplant	October 24, 2018	Phase 1
NCT04812548	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndrome (MDS)	May 31, 2021	Phase 2
NCT05262465	guomei\|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences	Adult Acute Myeloid Leukemia	July 1, 2020	Not Applicable
NCT04022785	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Myelodysplastic+Myeloproliferative Neoplasm\|Myeloproliferative Neoplasm	September 9, 2019	Phase 1
NCT04090736	PETHEMA Foundation\|Millennium Pharmaceuticals, Inc.\|Dynamic Science S.L.	Leukemia, Myeloid, Acute	September 24, 2019	Phase 3
NCT02829840	M.D. Anderson Cancer Center\|Ariad Pharmaceuticals	Leukemia\|FLT3-Mutated Acute Myeloid Leukemia\|FLT3-Mutated High-Risk Myelodysplastic Syndrome	September 2016	Phase 1\|Phase 2
NCT02953561	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	February 20, 2017	Phase 1\|Phase 2
NCT00934440	University of Kansas Medical Center\|Celgene	Renal Cell Carcinoma	June 2009	Phase 1\|Phase 2
NCT03593915	Sumitomo Pharma Oncology, Inc.	Myelodysplastic Syndromes (MDS)	August 29, 2018	Phase 1\|Phase 2
NCT04900350	Akeso	Myelodysplastic Syndrome	June 18, 2021	Phase 1\|Phase 2
NCT02343536	Celgene	Lymphoma, Large B-Cell, Diffuse\|Lymphoma, Follicular	April 29, 2015	Phase 1
NCT03013998	Beat AML, LLC	Previously Untreated Acute Myeloid Leukemia	November 2016	Phase 1\|Phase 2
NCT00915252	University Hospital Muenster\|Celgene Corporation\|Amgen	Acute Myeloid Leukemia	July 2009	Phase 2
NCT01566695	Celgene	Myelodysplastic Syndrome	April 26, 2013	Phase 3
NCT03146871	University of Southern California\|National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia\|Previously Treated Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes\|Recurrent Adult Acute Myeloid Leukemia	April 20, 2017	Phase 2
NCT03094637	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	High Risk Myelodysplastic Syndrome\|IPSS Risk Category Intermediate-1\|Myelodysplastic Syndrome	November 6, 2017	Phase 2
NCT04256317	Astex Pharmaceuticals, Inc.	Myelodysplastic Syndromes\|Chronic Myelocytic Leukemia\|Acute Myeloid Leukemia\|Myelodysplastic Syndrome+Neoplasm	May 21, 2020	Phase 2\|Phase 3
NCT02508870	Hoffmann-La Roche	Myelodysplastic Syndromes	September 30, 2015	Phase 1
NCT03586609	M.D. Anderson Cancer Center	Acute Myeloid Leukemia	October 25, 2018	Phase 2
NCT02577406	Celgene	Leukemia, Myeloid\|Isocitrate Dehydrogenase	December 30, 2015	Phase 3
NCT01186939	Celgene	Myelodysplastic Syndromes	April 1, 2007	Phase 3
NCT05201066	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	January 2, 2023	Phase 2
NCT05270200	Zhujiang Hospital	Leukemia, Myeloid, Acute	February 1, 2022	Phase 1\|Phase 2
NCT04797780	Syros Pharmaceuticals	Myelodysplastic Syndromes	February 8, 2021	Phase 3
NCT04417517	ALX Oncology Inc.	Higher Risk Myelodysplastic Syndromes	October 2, 2020	Phase 1\|Phase 2
NCT03450343	Medical University of South Carolina\|Celgene Corporation	Large B-Cell Diffuse Lymphoma	April 4, 2019	Phase 1
NCT01338337	Asociación Andaluza de Hematología y Hemoterapia	Myelodysplastic Syndrome (MDS)	November 2010	Phase 2
NCT04550442	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Genentech, Inc.	Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Myelodysplastic Syndrome\|Therapy-Related Myelodysplastic Syndrome	September 4, 2020	Phase 1\|Phase 2
NCT04128020	Sherif Farag\|Big Ten Cancer Research Consortium	Aml\|AML, Adult	October 10, 2019	Phase 1
NCT02785900	Seagen Inc.	Acute Myeloid Leukemia	May 2016	Phase 3
NCT02706899	Seagen Inc.	Myelodysplastic Syndrome	February 2016	Phase 1\|Phase 2
NCT00629343	Columbia University\|Schering-Plough\|Celgene Corporation	Soft Tissue Sarcoma\|Mesothelioma	October 2007	Phase 1
NCT02995655	Washington University School of Medicine\|Cantex Pharmaceuticals	Myelodysplastic Syndromes\|Acute Myeloid Leukemia\|AML\|MDS	April 7, 2017	Phase 1
NCT05554406	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic+Myeloproliferative Neoplasm\|Acute Myeloid Leukemia With Myelodysplasia-Related Changes\|Therapy-Related Acute Myeloid Leukemia	February 28, 2023	Phase 2
NCT03471260	M.D. Anderson Cancer Center	Acute Myeloid Leukemia\|Hematopoietic and Lymphoid System Neoplasm\|Myelodysplastic Syndrome\|Myeloproliferative Neoplasm\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	March 19, 2018	Phase 1\|Phase 2
NCT02775903	Celgene	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes	June 3, 2016	Phase 2
NCT04407442	University of California, San Francisco\|Janssen Pharmaceuticals\|Multiple Myeloma Research Foundation	Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	November 30, 2020	Phase 2
NCT01342692	Assistance Publique - Hôpitaux de Paris	MDS	June 2011	Phase 2
NCT03814005	Takeda	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic\|Leukemia, Myeloid, Acute\|Renal Insufficiency\|Liver Disease\|Neoplasms	July 10, 2019	Phase 1
NCT03895671	Versailles Hospital	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	June 19, 2019	Phase 2
NCT04139434	Newave Pharmaceutical Inc	AML+MDS\|CMML\|Relapse\|Refractory Acute Lymphoblastic Leukemia\|Relapse Leukemia\|Relapsed Adult AML	July 6, 2020	Phase 1
NCT05520567	Astellas Pharma Global Development, Inc.\|Astellas Pharma Inc	Acute Myeloid Leukemia (AML)\|FLT3-mutated Acute Myeloid Leukemia	November 2, 2022	Phase 1\|Phase 2
NCT01912274	Helsinn Healthcare SA	Acute Myeloid Leukemia	December 24, 2013	Phase 2
NCT01292083	University of Southern California\|National Cancer Institute (NCI)	Recurrent Breast Cancer\|Stage IA Breast Cancer\|Stage IB Breast Cancer\|Stage II Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer\|Triple-negative Breast Cancer	January 2011	Not Applicable
NCT04490707	Ge Zheng\|Zhongda Hospital	Acute Myeloid Leukemia in Remission	September 1, 2020	Phase 3
NCT01067274	Acute Leukemia French Association\|Assistance Publique - Hôpitaux de Paris	Acute Myeloid Leukemia	April 2010	Phase 3
NCT02341495	Elizabeth Henry\|Loyola University	Acute Myeloid Leukemia	February 2013	Phase 2
NCT02303782	Oncoethix GmbH	Acute Myeloid Leukemia	January 2015	Phase 1\|Phase 2
NCT00911066	Millennium Pharmaceuticals, Inc.	Acute Myelogenous Leukemia\|Acute Lymphoblastic Leukemia\|Myelodysplastic Syndrome	June 2009	Phase 1
NCT04372433	Immune-Onc Therapeutics\|California Institute for Regenerative Medicine (CIRM)	AML M5\|AML M4\|AML, Nos\|Acute Myelogenous Leukemia in Relapse\|Myelomonocytic Leukemia, Chronic	September 14, 2020	Phase 1
NCT03465540	Amgen	Multiple Myeloma\|Acute Myeloid Leukemia\|Non-Hodgkins Lymphoma\|Myelodysplastic Syndrome\|AML\|MDS\|NHL	August 17, 2018	Phase 1
NCT01083706	Fred Hutchinson Cancer Center\|Celgene Corporation\|National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Childhood Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	April 2010	Phase 2
NCT00658814	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Adult Acute Megakaryoblastic Leukemia\|Adult Acute Monoblastic Leukemia\|Adult Acute Monocytic Leukemia\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With Maturation\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL\|Adult Acute Myeloid Leukemia Without Maturation\|Adult Acute Myelomonocytic Leukemia\|Adult Erythroleukemia\|Adult Pure Erythroid Leukemia\|Secondary Acute Myeloid Leukemia	December 1, 2008	Phase 2
NCT01241786	Hackensack Meridian Health\|Celgene Corporation	Chronic Lymphocytic Leukemia(CLL)\|Small Lymphocytic Lymphoma	July 2010	Phase 2
NCT05433532	The First Affiliated Hospital of Soochow University	Philadelphia Chromosome\|Acute Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Chronic Myeloid Leukemia\|Mixed Phenotype Acute Leukemia	May 1, 2022	Phase 2
NCT03719989	Seoul National University Hospital	Diffuse Large B Cell Lymphoma\|Relapsed Non Hodgkin Lymphoma\|Refractory Non-Hodgkin Lymphoma	December 1, 2018	Phase 2
NCT00761722	Celgene	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Lymphoma\|Multiple Myeloma\|Leukemia, Myelomonocytic, Chronic	August 12, 2008	Phase 1
NCT04734990	M.D. Anderson Cancer Center	Chronic Myelomonocytic Leukemia-0\|Chronic Myelomonocytic Leukemia-1\|Chronic Myelomonocytic Leukemia-2\|Myelodysplastic Syndrome\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome	July 7, 2021	Phase 1\|Phase 2
NCT05211570	AB Science	Acute Myeloid Leukemia Refractory\|Acute Myeloid Leukemia, in Relapse\|Myelodysplastic Syndrome Acute Myeloid Leukemia	June 1, 2022	Phase 1\|Phase 2
NCT04730258	Treadwell Therapeutics, Inc	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|AML\|MDS\|CMML	April 16, 2021	Phase 1\|Phase 2
NCT04487106	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Myelodysplastic Syndrome	July 21, 2020	Phase 2
NCT01404741	Universitätsklinikum Hamburg-Eppendorf	Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia	July 2011	Phase 2
NCT03825367	Therapeutic Advances in Childhood Leukemia Consortium\|Bristol-Myers Squibb	AML, Childhood	November 29, 2019	Phase 1\|Phase 2
NCT02553941	Brian Jonas\|Pharmacyclics LLC.\|University of California, Davis	Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Previously Treated Myelodysplastic Syndrome\|Refractory Anemia With Excess Blasts in Transformation\|Secondary Myelodysplastic Syndrome	May 17, 2016	Phase 1
NCT01152346	Bioniche Pharma USA LLC	Myelodysplastic Syndrome	April 2011	Phase 1
NCT04061239	GWT-TUD GmbH	MDS\|AML	August 19, 2019	Phase 2
NCT02959437	Incyte Corporation	Solid Tumors\|Advanced Malignancies\|Metastatic Cancer	February 27, 2017	Phase 1\|Phase 2
NCT01305460	Groupe Francophone des Myelodysplasies	Myelodysplastic Syndrome	July 5, 2011	Phase 1\|Phase 2
NCT02147873	TetraLogic Pharmaceuticals	Myelodysplastic Syndrome (MDS)\|Chronic Myelomonocytic Leukemia (CMML)	June 2014	Phase 2
NCT05564390	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	February 28, 2023	Phase 2
NCT01281124	National Cancer Institute (NCI)	Recurrent Lung Non-Small Cell Carcinoma\|Stage IV Lung Non-Small Cell Cancer AJCC v7	January 12, 2011	Phase 2
NCT00387465	National Cancer Institute (NCI)	Recurrent Non-Small Cell Lung Carcinoma\|Stage IIIA Non-Small Cell Lung Cancer\|Stage IIIB Non-Small Cell Lung Cancer\|Stage IV Non-Small Cell Lung Cancer	August 2006	Phase 1\|Phase 2
NCT02421939	Astellas Pharma Global Development, Inc.\|Astellas Pharma Inc	Leukemia, Acute Myeloid (AML)	October 20, 2015	Phase 3
NCT02942758	University Hospital Regensburg\|Anticancer Fund, Belgium\|Celgene	Acute Myeloid Leukemia	April 10, 2017	Phase 2
NCT04278768	Curis, Inc.	Acute Myelogenous Leukemia\|Myelodysplastic Syndrome	July 6, 2020	Phase 1\|Phase 2
NCT03850418	Henry Ford Health System	Myeloid Malignancy	July 1, 2019	Phase 2
NCT05381038	National University Hospital, Singapore\|The N.1 Institute for Health (N.1)\|Cancer Science Institute of Singapore	Solid Tumor\|Gastrointestinal Cancer\|Breast Cancer	June 2022	Phase 1\|Phase 2
NCT03326310	University of Chicago	Chronic Myeloid Leukemia\|Myelofibroses	September 4, 2018	Phase 1
NCT01928576	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Rising Tide Foundation\|Stand Up To Cancer\|Bristol-Myers Squibb\|Celgene\|Syndax Pharmaceuticals, Inc.\|Rhone-Poulenc Rorer	Non-Small Cell Lung Cancer\|Epigenetic Therapy	August 2013	Phase 2
NCT03926624	Delta-Fly Pharma, Inc.	Leukemia, Myeloid, Acute	November 22, 2019	Phase 3
NCT02811497	University Health Network, Toronto	Microsatellite Stable Colorectal Carcinoma\|Platinum Resistant Epithelial Ovarian Cancer Type II\|Estrogen Receptor Positive and HER2 Negative Breast Cancer	September 2016	Phase 2
NCT00997243	Alison Walker\|Seagen Inc.\|Ohio State University Comprehensive Cancer Center	Leukemia\|Myelodysplastic Syndromes	November 2009	Phase 2
NCT05609942	Blueprint Medicines Corporation	Advanced Systemic Mastocytosis	December 1, 2022	Phase 1\|Phase 2
NCT01519011	Celgene	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic\|Leukemia, Myeloid, Acute	February 7, 2012	Phase 1
NCT03666559	Assistance Publique - Hôpitaux de Paris	Recurrent IDH1+2 Mutated Glioma	September 22, 2020	Phase 2
NCT01541280	Nantes University Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	November 2011	Phase 2
NCT01845805	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Pancreatic Cancer	January 10, 2014	Phase 2
NCT01093573	Brenda Cooper, MD\|National Cancer Institute (NCI)\|Case Comprehensive Cancer Center	Untreated Adult Acute Myeloid Leukemia	July 2009	Phase 1\|Phase 2
NCT01869114	Sidney Kimmel Cancer Center at Thomas Jefferson University\|Thomas Jefferson University	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|de Novo Myelodysplastic Syndromes\|Myelodysplastic Syndrome With Isolated Del(5q)\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Myeloid Leukemia	July 8, 2013	Phase 2
NCT03416179	Pfizer	Leukemia, Myeloid, Acute	April 20, 2018	Phase 3
NCT05453903	Janssen Research & Development, LLC	Leukemia, Myeloid, Acute	October 4, 2022	Phase 1
NCT00005934	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Institutes of Health Clinical Center (CC)	Beta Thalassemia	June 2000	Phase 2
NCT00392353	National Cancer Institute (NCI)	Acute Erythroid Leukemia\|Acute Megakaryoblastic Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts\|Myelodysplastic Syndrome With Ring Sideroblasts\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia	November 22, 2006	Phase 1\|Phase 2
NCT05404906	The First Affiliated Hospital of Soochow University	Acute Myeloid Leukemia (AML) in Remission	June 25, 2022	Phase 2\|Phase 3
NCT02701673	M.D. Anderson Cancer Center	Lymphoma	June 2016	Phase 1\|Phase 2
NCT01201811	Celgene	Myelodysplastic Syndromes	October 1, 2010	Phase 4
NCT04214860	Aprea Therapeutics	Myeloid Malignancy	December 13, 2019	Phase 1
NCT00813124	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Celgene Corporation	Stem Cell Transplantation\|Leukemia	December 2008	Phase 2
NCT02711137	Incyte Corporation	Solid Tumors	May 18, 2016	Phase 1\|Phase 2
NCT01839240	University of Chicago\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	June 6, 2012	Phase 1
NCT00741234	S*BIO	Solid Tumors\|Hematologic Malignancies\|Myelodysplastic Syndrome	April 2007	Phase 1
NCT04187703	Benjamin Tomlinson\|Case Comprehensive Cancer Center	Myelodysplastic Syndromes\|MDS+MPN Crossover Syndromes	November 16, 2020	Early Phase 1
NCT04485065	Innovent Biologics (Suzhou) Co. Ltd.	Myelodysplastic Syndromes	September 30, 2020	Phase 1
NCT04638309	Aprea Therapeutics	MDS\|Myelodysplastic Syndromes	September 20, 2021	Phase 1
NCT04801797	Massachusetts General Hospital\|AbbVie	Acute Myeloid Leukemia	May 20, 2021	Phase 2
NCT01460498	M.D. Anderson Cancer Center\|Celgene Corporation	Leukemia	August 8, 2012	Phase 1
NCT01249430	National Cancer Institute (NCI)	Recurrent Adult Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	January 20, 2011	Phase 1
NCT03298516	Genentech, Inc.	Leukemia, Myeloid, Acute	November 15, 2017	Phase 1
NCT01390311	Washington University School of Medicine\|National Cancer Institute (NCI)	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes	April 2012	Phase 1
NCT00004871	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Diseases	May 2000	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H ₂ O : 33.33 mg/mL ( 136.49 mM ; Need ultrasonic)

DMSO : ≥ 31 mg/mL ( 126.95 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.0950 mL	20.4750 mL	40.9500 mL
5 mM	0.8190 mL	4.0950 mL	8.1900 mL
10 mM	0.4095 mL	2.0475 mL	4.0950 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 20 mg/mL (81.90 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (8.52 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (8.52 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (8.52 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl-

s-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl-

4-Amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one

Antibiotic U 18496

5-Azacytidine

U 18496

NSC 102816

Azacitidine

Azacytidine

NSC 103-627

5-AZCR

Mylosar

5-AC

WR 183027

5-AzaC

5-AZC

Ladakamycin

Ledakamycin

Vidaza

CC 486

5-Azacitidine